Yale Researchers Find That Ubiquitous Protein Plays Lead Role in Cell Survival
Yale researchers have discovered that the protein polycystin 2 protects against cell death, making it a potential target for therapies to treat a variety of diseases of the liver and kidneys, as well as for brain aneurysms, heart disease, and cancer.
Rothlin Is Appointed McConnell Duberg Professor
Carla Vanina Rothlin, PhD, newly named as Dorys McConnell Duberg Professor of Immunobiology, studies the mechanisms that regulate the magnitude and resolution of the immune response. Rothlin is also a professor of pharmacology, a member of the Yale Cancer Center, and a Howard Hughes Faculty Scholar.
Picciotto to be Recognized with Marion Spencer Fay Award
The Institute for Women’s Health and Leadership of Drexel University College of Medicine will award its 2020 Marion Spencer Fay Award to Marina Picciotto, PhD, Charles B.G. Murphy Professor of Psychiatry and Professor in the Child Study Center, of Neuroscience and of Pharmacology at Yale School of Medicine.
New Strategy for Untreatable Kidney Disease: Targeting Cell Energy
The best hope for people with an inherited form of kidney disease that causes kidney failure is dialysis or a kidney transplant. But a study led by Yale researchers reveals a potential strategy for developing new drug therapies for these patients.
Our antibiotics are no match for superbugs, and it's a 'global crisis,' UN report says
(CNN)Common diseases such as tuberculosis are becoming untreatable while lifesaving medical procedures like surgeries carry increasing risks because of "alarming levels" of resistance to antimicrobial drugs, according to a new United Nations committee report. Resistance to antibiotics, antivirals, antifungals and antiprotozoals, which has been seen in countries of all income levels, is now a "global crisis," the authors wrote.Source: CNN
Don't Jump for Joy over New FDA-approved Postpartum Depression Medicine Yet
Kimberly Yonkers, MD, Professor of Psychiatry, of Epidemiology (Chronic Diseases) and of Obstetrics, Gynecology, and Reproductive Sciences cautions new mothers who may consider taking the new FDA-approved medication for postpartum depression in an opinion piece published in USA Today.Source: USA Today
North American Vascular Biology Organization Honors Eichmann and Sessa
The North American Vascular Biology Organization will give its Judah Folkman Award in Vascular Biology to Anne Eichmann, PhD, Ensign Professor of Medicine (Cardiology) and professor of cellular and molecular physiology; and its Earl P. Benditt Award to William Sessa, PhD, Alfred Gilman Professor of Pharmacology and professor of medicine (cardiology).
Department of Pharmacology Mini-symposium on Feb. 11
The Department of Pharmacology is hosting a mini-symposium titled, "The Biology of Endocrine FGFs: From Basic Mechanisms to Therapeutic Opportunities" on Monday, February 11th, 2019 from 9:30am to 12:30pm (TAC N107). This mini-symposium will feature three separate lectures from three distinguished speakers.
New compound targets drug-resistant HIV mutants
Antiretroviral therapies have worked wonders suppressing HIV replication and its progression to AIDS, but their effectiveness is deteriorating due to the constant development of drug resistance in the virus. Now Yale researchers have shown their newly developed compounds maintain anti-HIV activity against drug-resistant mutants better than FDA-approved medications.
Human insulin as safe and effective to treat type 2 diabetes as costlier insulin analogs
Patients with Type 2 diabetes who were treated with the newer generation of insulin analog drugs did not have substantially better outcomes than those treated with less costly human insulin, according to a study by Yale School of Medicine researchers and colleagues at Kaiser Permanente.
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Apexigen, Inc., and Yale Cancer Center today announced a clinical trial collaboration to evaluate Apexigen's APX005M in combination with cabiralizumab and Opdivo in patients with advanced solid tumors. The Phase 1/2 clinical trial will evaluate the safety, tolerability, and preliminary activity of APX005M in combination with cabiralizumab and Opdivo in metastatic NSCLC, metastatic melanoma and RCC patients whose disease has progressed on prior anti-PD-1/PD-L1 therapy (www.clinicaltrials.gov: NCT03502330). In addition to providing funding, Bristol-Myers Squibb will supply Opdivo and cabiralizumab, an investigational antibody being developed in partnership with Five Prime Therapeutics.